Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report)’s stock price was down 3.9% on Wednesday . The stock traded as low as $162.42 and last traded at $162.77. Approximately 159,726 shares traded hands during mid-day trading, a decline of 56% from the average daily volume of 365,231 shares. The stock had previously closed at $169.35. […]
HC Wainwright reiterated their buy rating on shares of Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has a $225.00 price target on the biopharmaceutical company’s stock. Several other equities analysts have also issued reports on the company. Canaccord Genuity Group reissued a […]
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report)‘s stock had its “neutral” rating reissued by equities research analysts at B. Riley in a note issued to investors on Monday, Benzinga reports. They currently have a $224.00 price objective on the biopharmaceutical company’s stock. B. Riley’s target price indicates a potential upside of 26.65% from the company’s […]
Logos Global Management LP lessened its stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 16.7% in the first quarter, HoldingsChannel.com reports. The firm owned 50,000 shares of the biopharmaceutical company’s stock after selling 10,000 shares during the quarter. Madrigal Pharmaceuticals accounts for 1.7% of Logos Global Management LP’s portfolio, making the stock its […]
B. Riley reiterated their neutral rating on shares of Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) in a research note issued to investors on Tuesday, Benzinga reports. B. Riley currently has a $224.00 target price on the biopharmaceutical company’s stock. MDGL has been the topic of several other research reports. StockNews.com initiated coverage on Madrigal Pharmaceuticals […]